Cobra Biomanufacturing Plc Company Profile

19:48 EDT 24th March 2018 | BioPortfolio

“Our experience combined with an innovative approach gives us the ability to accelerate development time lines and reduce project risk, enabling our customer’s goals to be reached efficiently and effectively, and come with full regulatory support..


3020 El Cerrito Plaza #300
El Cerrito
United States of America


Phone: 1 703 591-2468

News Articles [64 Associated News Articles listed on BioPortfolio]

Cobra awarded £2.6m from Innovate UK for expansion

Keele, UK-based Cobra Biologics is being handed £2.6 million by Innovate UK to help the firm expand and develop its infrastructure.

Infinisource Benefit Services reaches 10 million COBRA notices milestone

Although the COBRA law is over 30 years old, it still causes confusion for many employers. There are numerous required notices and tasks related to Read more...

Lilly to pump $1.2bn into its biomanufacturing in 2018

Eli Lilly has projected an increased spend across its biomanufacturing network next year to support bulk production and fill/finish of monoclonal antibodies.

Amgen: Tax reforms stoke $300m investment in next-gen US biomanufacturing plant

Amgen has announced plans for a US biomanufacturing facility, similar to its flexible and single-use Singapore plant, as part of $3.5bn freed through tax reforms.

Cobra Biologics and Symbiosis granted £1.9 million from Innovate UK

International CDMO of biologics and pharmaceuticals, Cobra Biologics, and CMO specialising in sterile fill finish, Symbiosis Pharmaceutical Services, have been awarded a collaborative grant of £1.9 m...

GE to provide biomanufacturing platform for Clover’s Chinese facility

GE Healthcare will provide its biomanufacturing platform for Clover Biopharmaceuticals’ new production facility in China.

Ingenza advances inABLE® biomanufacturing technologies in collaboration with Syngenta

The post Ingenza advances inABLE® biomanufacturing technologies in collaboration with Syngenta appeared first on SynBioBeta.

Ventria Wins $4.2M Gates Foundation Grant Toward Biomanufacturing ETEC Therapeutics

Ventria Bioscience said today it has won a $4.2 million grant from the Bill & Melinda Gates Foundation toward the biomanufacturing of new therapeutics targeting Enterotoxigenic Escherichia coli (E...

Drugs and Medications [0 Results]


PubMed Articles [23 Associated PubMed Articles listed on BioPortfolio]

Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent.

The COBRA PzF coronary stent, which has a unique nano-coating of Polyzene-F, was developed to reduce the risk of stent thrombosis.

New paradoxical three-finger toxin from the cobra Naja kaouthia venom: Isolation and characterization.

A new three-finger toxin nakoroxin was isolated from the cobra Naja kaouthia venom, and its complete amino acid sequence was established. Nakoroxin belongs to the group of "orphan" toxins, data on the...

Tailoring cyanobacterial cell factory for improved industrial properties.

Photosynthetic biomanufacturing provides a promising solution for sustainable production of biofuels and biochemicals. Cyanobacteria are among the most promising microbial platforms for the constructi...

Combined Bisulfite Restriction Analysis for brain tissue identification.

According to the tissue-specific methylation database (doi: 10.1016/j.gene.2014.09.060), methylation at CpG locus cg03096975 in EML2 has been preliminarily proven to be specific to brain tissue. In th...

First Look at the Venom of Naja ashei.

is an African spitting cobra species closely related toand. It is known that the venom of, like that of other African spitting cobras, mainly has cytotoxic effects, however data about its specific pro...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease

To demonstrate the safety and efficacy of the Cobra Cobalt Super Alloy Balloon-Expandable Coronary Stent System for the treatment of de novo and restenotic (previously unstented) lesions i...

Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry

A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary v...

Renal Agenesis Fetal Therapy

This study offers eligible pregnant patients with a fetal diagnosis of congenital bilateral renal agenesis (CoBRA) serial amnioinfusions with normal saline. All eligible patients will be o...

Companies [32 Associated Companies listed on BioPortfolio]

Therapure Biopharma Inc.

Therapure Biomanufacturing is a global contract development and manufacturing organization (CDMO) offering integrated services for developing, manufacturing, purifying and packagi...

Therapure Biomanufacturing

Cobra Biomanufacturing Plc

“Our experience combined with an innovative approach gives us the ability to accelerate development time lines and reduce project risk, enabling our customer’s goals to be reached efficiently and ...

Q One Biotech Limited

biosafety testing, biomanufacturing, genetherapy, and virus validation studies.

Q-One Biotech Limited

QOne Biotech, Ltd. biosafety testing, biomanufacturing, gene therapy, and virus validation studies.

More Information about "Cobra Biomanufacturing Plc" on BioPortfolio

We have published hundreds of Cobra Biomanufacturing Plc news stories on BioPortfolio along with dozens of Cobra Biomanufacturing Plc Clinical Trials and PubMed Articles about Cobra Biomanufacturing Plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cobra Biomanufacturing Plc Companies in our database. You can also find out about relevant Cobra Biomanufacturing Plc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record